Blockchain Enabled Healthcare
The PharmaLedger project aims at developing a blockchain-based platform that will enable trusted and privacy-enabled digital collaboration through knowledge sharing among the healthcare stakeholders; supporting highly compliant and interoperable data exchange among members of the pharmaceutical and healthcare value chain.
The PharmaLedger platform builds on the pillars of blockchain (decentralization, transparency, and immutability), provides a set of services to ensure regulatory, legal and data privacy compliance, and will be validated through a set of use cases in three reference implementations: supply chain, clinical trials and health data. For us, this privacy-enabled, and efficient foundation using blockchain will help to emerge a stronger and trustworthy healthcare ecosystem.
Moreover, the PharmaLedger consortium drives on early adoption of a disruptive blockchain-based digitization technology, with key industry participants joining forces to build a comprehensive solution for improving the quality of healthcare. A governance framework is being developed for this blockchain-based pharmaceutical and healthcare ecosystem; which shall allow stakeholders to benefit from the adoption of PharmaLedger and reap large efficiency, de-risking, cost reduction, and simplified compliance.
To bring this platform to life, PharmaLedger focuses on validating the platform on a set of use cases from three reference implementations domains: supply chain, clinical trials and health data. These early implementations throughout each referenced domain provide evidence to create value and trust to unlock the potential of the digital healthcare ecosystem, especially to patients.
PharmaLedger is a three year Project started on January 2020 receiving funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853992. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. PharmaLedger is driven by a private-public consortium with 29 partners (12 global pharmaceutical companies and 17 public and private entities).